What is Circle Pharma?
Circle Pharma operates a sophisticated, indication-agnostic discovery engine designed to develop novel cell-permeable macro-cyclic peptide therapeutics. The company leverages a computational structure-based design approach to target challenging therapeutic areas that are difficult to address with conventional small molecules. Founded in 2012 and headquartered in San Francisco, California, Circle Pharma is positioned at the forefront of peptide therapeutics innovation, aiming to unlock new treatment modalities for a range of diseases.
How much funding has Circle Pharma raised?
Circle Pharma has raised a total of $204.8M across 4 funding rounds:
Series A
$3.8M
Series B
$45M
Series C
$66M
Series D
$90M
Series A (2016): $3.8M with participation from Pfizer Inc, Mission Bay Capital, and ShangPharma Investment Group, Ltd
Series B (2020): $45M led by Berkeley Catalyst Fund, ShangPharma Innovation Inc, Nextech Invest Ltd, Lifeforce Capital, and The Column Group
Series C (2021): $66M supported by Euclidean Capital, Hartford HealthCare Endowment, The Column Group, Pavillion Capital, Eli Lilly and Company, Nextech Invest, and Pandect Bioventures
Series D (2024): $90M featuring Nextech Invest, The Column Group, and Euclidean Capital
Key Investors in Circle Pharma
Nextech Invest
Nextech Invest is a Zurich-based company dedicated to accelerating advancements in precision medicine by identifying transformative cancer medicines. They focus on nurturing emerging biotechnology companies worldwide, particularly during critical moments of scientific validation and value creation.
The Column Group
The Column Group (TCG) is a venture ecosystem focused on advancing scientific innovation in the life sciences sector. With a history of funding key advancements in biotechnology, TCG has supported the formation and growth of 55 companies, generating $4.0 billion in returns for its partners.
Pfizer Inc
Pfizer is a biopharmaceutical company that researches, develops, manufactures, and markets medicines and vaccines across multiple therapeutic areas. The company focuses on areas such as oncology, internal medicine, inflammation and immunology, and vaccines to help prevent, treat, and manage disease worldwide.
What's next for Circle Pharma?
The recent major strategic investment in Circle Pharma signals a strong validation of its technology and therapeutic approach. This capital infusion is expected to accelerate the company's pipeline development, potentially enabling it to move promising drug candidates through further preclinical and clinical stages. The company's focus on challenging therapeutic targets suggests a long-term strategy aimed at addressing unmet medical needs, positioning it for significant growth and potential market disruption in the biopharmaceutical sector.
See full Circle Pharma company page
